Key Points Regeneron's latest financial results were strong. The company is finding ways to overcome a recent patent cliff. Despite more challenges on the horizon, the biotech's prospects look bright. 10 stocks we like better than Regeneron Pharmaceuticals › Regeneron Pharmaceuticals ' (NASDAQ: REGN) shares climbed well above $1,000 two years ago, reaching all-time highs. However, they have dropped significantly from those levels over the past 24 months and now sit slightly below $800 apiece. What has happened to Regeneron? Is the stock a great buy at current levels? Let's find out. Recent financial results In the second quarter, Regeneron's revenue increased by 17% year over year to $4.3 billion.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.